Aquarius Surgical Technologies Announces Share Issuance

2 years ago

TORONTO, ON / ACCESSWIRE / March 25, 2022 / Aquarius Surgical Technologies Inc. (CSE:ASTI) announces that it has issued 100,000…

Xcelerate, Inc. Files Medical Surgical Device Patent

2 years ago

MAULDIN, SC / ACCESSWIRE / March 25, 2022 / Xcelerate, Inc. (OTC Markets:XCRT) recently announced that it signed a Membership…

NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference

2 years ago

ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss…

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

2 years ago

International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise…

CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma

2 years ago

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large…

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

2 years ago

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line…

Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

2 years ago

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared…

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe

2 years ago

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment…

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

2 years ago

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with…